-
1
-
-
0027955973
-
Agents for treating human immunodeficiency virus infection
-
Acosta E. Fletcher C. Agents for treating human immunodeficiency virus infection. AM J Hosp Pharm l994; 51:2251-67
-
(1994)
AM J Hosp Pharm
, vol.51
, pp. 2251-2267
-
-
Acosta, E.1
Fletcher, C.2
-
2
-
-
0030596902
-
Antiretroviral drugs for AIDS
-
Lipsky J. Antiretroviral drugs for AIDS. Lancet 1996;348:800-3
-
(1996)
Lancet
, vol.348
, pp. 800-803
-
-
Lipsky, J.1
-
3
-
-
0027316173
-
Therapy for human immunodeficiency virus infection
-
Hirsch M, D'Aquila R. Therapy for human immunodeficiency virus infection. N Engl J Med 1993;328:1686-95
-
(1993)
N Engl J Med
, vol.328
, pp. 1686-1695
-
-
Hirsch, M.1
D'Aquila, R.2
-
4
-
-
0003127637
-
AIDS testing now and in the future
-
Sande M, Volberding P, eds. Philadelphia, W. B. Saunders Co.
-
Saag M. AIDS testing now and in the future. In Sande M, Volberding P, eds. The Medical Management of AIDS. Philadelphia, W. B. Saunders Co., 1995:65-88
-
(1995)
The Medical Management of AIDS
, pp. 65-88
-
-
Saag, M.1
-
5
-
-
0030070991
-
Prognosis in HIV-1 infection predicted by the quantity of virus in plasma
-
Mellors J, Rinaldo C, Gupta P, et al. Prognosis In HIV-1 infection predicted by the quantity of virus in plasma. Science 1996;272:1167-70
-
(1996)
Science
, vol.272
, pp. 1167-1170
-
-
Mellors, J.1
Rinaldo, C.2
Gupta, P.3
-
9
-
-
0029781541
-
Can researchers use new drugs to push HIV envelope to extinction?
-
Voelker R. Can researchers use new drugs to push HIV envelope to extinction? JAMA 1996;276(6):435-437
-
(1996)
JAMA
, vol.276
, Issue.6
, pp. 435-437
-
-
Voelker, R.1
-
10
-
-
0345334246
-
Antiretroviral therapy for HIV infection in 1996
-
Carpenter C, Fischl M, Hammer S, et al. Antiretroviral therapy for HIV infection in 1996. JAMA 1996;276(2): 146-154
-
(1996)
JAMA
, vol.276
, Issue.2
, pp. 146-154
-
-
Carpenter, C.1
Fischl, M.2
Hammer, S.3
-
11
-
-
1842266562
-
HIV viral load markers in clinical practice
-
Saag M, Holodniy M, Kuritzkes D. HIV viral load markers in clinical practice. Nature Medicine 1996;2(6):625-9
-
(1996)
Nature Medicine
, vol.2
, Issue.6
, pp. 625-629
-
-
Saag, M.1
Holodniy, M.2
Kuritzkes, D.3
-
12
-
-
85036446570
-
Bringing state of the art guidelines to clinical practice
-
July 7-12 Vancouver, Canada
-
Carpenter C, Volberding P, Richman D, et al. Bringing state of the art guidelines to clinical practice. As presented in HIV in Focus: A Daily Reporting Service from the XI International Conference on AIDS; July 7-12 Vancouver, Canada. 1996;5:7-8
-
(1996)
As Presented in HIV in Focus: A Daily Reporting Service from the XI International Conference on AIDS
, vol.5
, pp. 7-8
-
-
Carpenter, C.1
Volberding, P.2
Richman, D.3
-
13
-
-
0029791166
-
New strategies to combat HIV drug resistance
-
Richman D. New strategies to combat HIV drug resistance. Hospital Practice 1996;August 15:47-58
-
(1996)
Hospital Practice
, vol.AUGUST 15
, pp. 47-58
-
-
Richman, D.1
-
16
-
-
0002955605
-
Clinical relevance of cytochrome P-450 enzymes
-
Slaughter, R. Clinical relevance of cytochrome P-450 enzymes. Hospital Pharmacy Times 1996;July:6-14
-
(1996)
Hospital Pharmacy Times
, vol.JULY
, pp. 6-14
-
-
Slaughter, R.1
-
17
-
-
85036447118
-
-
Saquinavir Package Insert. Hoffman-La Roche Inc., Nutley, NJ
-
Saquinavir Package Insert. Hoffman-La Roche Inc., Nutley, NJ
-
-
-
-
18
-
-
0343323330
-
Saquinavir (Invirase SQV) vs. Hivid (Zalcitabine, ddC) vs. combination as treatment for advanced HIV infection in patients discontinuing/unable to take retrovir (Zidovudine, ZDV)
-
July 7-12; Vancouver, Canada
-
Salgo M, Beattie D, Bragman K, et al. Saquinavir (Invirase SQV) vs. Hivid (Zalcitabine, ddC) vs. combination as treatment for advanced HIV infection in patients discontinuing/unable to take retrovir (Zidovudine, ZDV). Presented at the XI International Conference on AIDS; July 7-12; Vancouver, Canada
-
XI International Conference on AIDS
-
-
Salgo, M.1
Beattie, D.2
Bragman, K.3
-
19
-
-
0029897059
-
Saquinavir: A review of its pharmacology and clinical potential in the management of HIV infection
-
Noble S, Faulds D. Saquinavir: A review of its pharmacology and clinical potential in the management of HIV infection. Drugs 1996;52(1):94-112
-
(1996)
Drugs
, vol.52
, Issue.1
, pp. 94-112
-
-
Noble, S.1
Faulds, D.2
-
20
-
-
85036445365
-
-
Hoffman-La Roche Inc., Nutley, NJ
-
Saquinavir Data on File. Hoffman-La Roche Inc., Nutley, NJ
-
Saquinavir Data on File
-
-
-
21
-
-
85036447528
-
-
Saquinavir Investigation Drug Brochure. Hoffman-La Roche, Nutley, NJ
-
Saquinavir Investigation Drug Brochure. Hoffman-La Roche, Nutley, NJ
-
-
-
-
22
-
-
2442723342
-
Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine
-
Collier A, Coombs R, Schoenfeld D, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Engl J Med 1996;334:1011-7
-
(1996)
N Engl J Med
, vol.334
, pp. 1011-1017
-
-
Collier, A.1
Coombs, R.2
Schoenfeld, D.3
-
23
-
-
85036447881
-
Synergistic action between ritonavir and saquinavir: Implications for treatment
-
July 11 Vancouver, Canada
-
Cameron B. Synergistic action between ritonavir and saquinavir: implications for treatment. As presented in Satellite Symposium Highlights from the XI International Conference on AIDS; July 11 Vancouver, Canada. 1996:6
-
(1996)
Satellite Symposium Highlights from the XI International Conference on AIDS
, pp. 6
-
-
Cameron, B.1
-
24
-
-
0342480525
-
New antiretroviral agents: Review and recommendations
-
July
-
New antiretroviral agents: Review and recommendations. HIV Clinical Information Network 1996, July
-
(1996)
HIV Clinical Information Network
-
-
-
25
-
-
0030419674
-
Drug-food interactions with grapefruit juice
-
Rodvold K, Meyer J. Drug-food interactions with grapefruit juice. Infect Med 1996; 13(10):868, 871-3,912
-
(1996)
Infect Med
, vol.13
, Issue.10
, pp. 868
-
-
Rodvold, K.1
Meyer, J.2
-
26
-
-
85036448511
-
-
Abbott Laboratories North Chicago, IL
-
Ritonavir Product Labeling. Abbott Laboratories North Chicago, IL
-
Ritonavir Product Labeling
-
-
-
27
-
-
0028806725
-
A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection
-
Markowitz, M, Saag M, Powderly W, et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med 1995;333:1534-9
-
(1995)
N Engl J Med
, vol.333
, pp. 1534-1539
-
-
Markowitz, M.1
Saag, M.2
Powderly, W.3
-
28
-
-
85036439109
-
-
Abbott Laboratories, North Chicago, IL
-
Ritonavir Data on File. Abbott Laboratories, North Chicago, IL
-
Ritonavir Data on File
-
-
-
31
-
-
0343785721
-
New directions in chemoprophylaxis and treatment of disseminated Mycobacterium avium complex disease
-
New Orleans, LA
-
Benson C. New directions in chemoprophylaxis and treatment of disseminated Mycobacterium avium complex disease. Presentation at the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1996. New Orleans, LA
-
(1996)
36th Interscience Conference on Antimicrobial Agents and Chemotherapy
-
-
Benson, C.1
-
32
-
-
85036449194
-
-
Merck & Co., Inc., West Point, PA
-
Indinavir Product Labeling. Merck & Co., Inc., West Point, PA
-
Indinavir Product Labeling
-
-
-
33
-
-
85036443129
-
-
Merck & Co., Inc., West Point, PA
-
Indinavir Data on File. Merck & Co., Inc., West Point, PA
-
Indinavir Data on File
-
-
-
34
-
-
85036440353
-
-
Press Release September 16, 1996. Agouron Pharmaceuticals, La Jolla, CA
-
Press Release September 16, 1996. Agouron Pharmaceuticals, La Jolla, CA
-
-
-
-
35
-
-
85036443864
-
-
Agouron Pharmaceuticals, La Jolla, CA
-
Nelfinavir Data on file. Agouron Pharmaceuticals, La Jolla, CA
-
Nelfinavir Data on file
-
-
-
36
-
-
85036441109
-
-
Press Release January 30,1996. Agouron Pharmaceuticals, La Jolla, CA
-
Press Release January 30,1996. Agouron Pharmaceuticals, La Jolla, CA
-
-
-
-
37
-
-
85036447161
-
-
Press Release May 20, 1996. Agouron Pharmaceuticals. La Jolla, CA
-
Press Release May 20, 1996. Agouron Pharmaceuticals. La Jolla, CA
-
-
-
-
38
-
-
85036449986
-
-
Press Release July 8, 1996. Agouron Pharmaceuticals, La Jolla, CA
-
Press Release July 8, 1996. Agouron Pharmaceuticals, La Jolla, CA
-
-
-
|